H.I.G. HealthBridge Partners

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Arvelle Therapeutics GmbH is a biopharmaceutical company headquartered in Zug, Switzerland, founded in 2019. The company is dedicated to developing and commercializing innovative treatments for patients suffering from central nervous system (CNS) disorders. Its primary focus is on cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients experiencing focal seizures. Through its efforts, Arvelle Therapeutics seeks to enhance the quality of care available to individuals affected by debilitating neurological and neuromuscular diseases.

Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.

Arvelle Therapeutics GmbH is a biopharmaceutical company headquartered in Zug, Switzerland, founded in 2019. The company is dedicated to developing and commercializing innovative treatments for patients suffering from central nervous system (CNS) disorders. Its primary focus is on cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients experiencing focal seizures. Through its efforts, Arvelle Therapeutics seeks to enhance the quality of care available to individuals affected by debilitating neurological and neuromuscular diseases.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Neurana Pharmaceuticals is a biotechnology company based in San Diego, California, focused on developing treatments for neuromuscular conditions. Founded in 2013, the company specializes in addressing acute and painful muscle spasms of the neck and back. Neurana's flagship therapeutic compound is Tolperisone, which treats musculoskeletal conditions such as neuromuscular spasms and spasticity without causing sedation. The company aims to provide fast relief for patients suffering from these conditions.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals to address rare gastrointestinal conditions in infants. Based in Ramat-Gan, Israel, the company has created oral formulations of insulin designed to enhance gut adaptation and rehabilitation in premature infants and children. Its key clinical programs include NTRA-2112, which aims to reduce enteral nutrition intolerance, promote growth velocity and weight gain, and decrease the length of stay in neonatal intensive care units. Another significant product, NTRA-9620, targets short bowel syndrome by improving bowel adaptation post-resection, facilitating enteral nutrition, and minimizing the reliance on parenteral nutrition. Founded in 2003, Nutrinia is committed to improving the health outcomes of vulnerable populations through innovative scientific solutions.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Orbus Therapeutics, Inc., established in 2012 and based in Palo Alto, California, is a biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases, with a focus on brain cancers. Its lead product, Eflornithine, is an orally bioavailable small molecule that acts as a cytostatic agent, inhibiting tumor growth by targeting ornithine decarboxylase (ODC). Currently, Orbus Therapeutics is working to bring Eflornithine to patients in North America affected by recurrent anaplastic astrocytoma, a rare and life-threatening form of central nervous system cancer. The company's mission is to improve the health and quality of life for these underserved patients by delivering innovative products that offer more positive outcomes.

RxSight, Inc. is a medical technology company based in Aliso Viejo, California, focused on enhancing vision for patients after cataract surgery. It has developed the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL), a Light Delivery Device (LDD), and associated accessories. This innovative technology is the first of its kind to allow healthcare professionals to customize and optimize visual acuity post-surgery, enabling precise reshaping of the lens to meet individual patient needs. Additionally, the LAL features ActivShield technology, providing built-in UV protection. Established in 1997 and originally named Calhoun Vision, Inc., the company rebranded to RxSight, Inc. in 2017.

RxSight, Inc. is a medical technology company based in Aliso Viejo, California, focused on enhancing vision for patients after cataract surgery. It has developed the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL), a Light Delivery Device (LDD), and associated accessories. This innovative technology is the first of its kind to allow healthcare professionals to customize and optimize visual acuity post-surgery, enabling precise reshaping of the lens to meet individual patient needs. Additionally, the LAL features ActivShield technology, providing built-in UV protection. Established in 1997 and originally named Calhoun Vision, Inc., the company rebranded to RxSight, Inc. in 2017.

NeuWave Medical is a company based in Madison, Wisconsin, that specializes in the development of energy-based minimally invasive medical devices. Founded in 2004 by a team of engineers and physician-scientists, NeuWave Medical is dedicated to addressing clinical needs through innovative solutions that are both effective and minimally invasive. The company aims to create high-quality devices that are preferred by leading physicians and medical centers worldwide, focusing on treating a variety of serious medical conditions.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.

Cardeas Pharma is focused on developing an innovative antibiotic formulation that combines two drugs to target highly resistant Gram-negative bacilli, such as Pseudomonas aeruginosa and Acinetobacter baumannii, as well as carbapenem-resistant Enterobacteriaceae. This formulation is designed to treat serious respiratory infections in critical care settings, particularly those caused by antibiotic-resistant organisms. Additionally, it demonstrates efficacy against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and has activity on biofilms. The delivery system utilizes a single-patient use, vibrating-plate nebulizer compatible with all ventilators, which generates small, uniform aerosol droplets that effectively reach the small airways and alveoli. By integrating this novel antibiotic formulation with advanced drug-delivery technology, Cardeas Pharma aims to achieve substantial clinical improvements over current treatment standards.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in the development of non-invasive drug delivery technologies aimed at treating major eye diseases such as glaucoma, dry eye, and allergies. The company is focused on creating innovative products that can replace traditional eye drops and offer sustained therapeutic effects. Currently, ForSight VISION5 is advancing its lead product, the Helios insert, which is undergoing its second Phase 2 clinical study, reflecting the company's commitment to improving patient care in ophthalmology through effective and patient-friendly solutions.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

ForSight Labs is a company dedicated to developing innovative ophthalmic technologies aimed at improving the sight, care, and quality of life for visually impaired patients. With a focus on addressing the significant challenges posed by vision loss, including conditions like glaucoma, ForSight Labs collaborates with a team of motivated professionals, clinicians, and investors to bring new solutions to the ophthalmic community. The company recognizes the profound impact of vision impairment on individuals and society, as the number of people suffering from visual impairment is expected to increase significantly in the coming years. By driving the development and commercialization of high-impact eye care technologies, ForSight Labs aims to deliver effective treatments that enhance patient outcomes and address the substantial economic burden associated with vision loss.

Cerephex Corporation, established in 2012 and headquartered in Los Altos, California, specializes in developing non-invasive technologies for treating chronic centralized pain conditions. The company's primary product is NeuroPoint, a point-of-care medical device platform utilizing reduced impedance noninvasive cortical electrostimulation signal technology to target and modulate brain function in areas associated with central sensitivity. Cerephex offers NeuroPoint for use by physician-supervised staff in existing clinical outpatient offices, aiming to manage conditions like fibromyalgia under FDA approval.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.

NeuWave Medical is a company based in Madison, Wisconsin, that specializes in the development of energy-based minimally invasive medical devices. Founded in 2004 by a team of engineers and physician-scientists, NeuWave Medical is dedicated to addressing clinical needs through innovative solutions that are both effective and minimally invasive. The company aims to create high-quality devices that are preferred by leading physicians and medical centers worldwide, focusing on treating a variety of serious medical conditions.